Emerging from stealth, the company is debuting NEXUS, a Large Tabular Model (LTM) designed to treat business data not as a ...
Emerging from stealth, the company is debuting NEXUS, a Large Tabular Model (LTM) designed to treat business data not as a ...
This study addresses endosomal escape in oligonucleotide therapies and how engineered peptides can enhance intracellular drug delivery efficiency.
Q4 2025 Earnings Call February 5, 2026 8:00 AM ESTCompany ParticipantsJean-Laurent Bonnafe - MD, CEO & DirectorLars Machenil ...